Literature DB >> 7472820

Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations.

M Wilschanski1, J Zielenski, D Markiewicz, L C Tsui, M Corey, H Levison, P R Durie.   

Abstract

OBJECTIVE: To compare differences in epithelial chloride conductance according to class of mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
METHODS: We evaluated the relationship between the functional classes of CFTR mutations and chloride conductance using the first diagnostic sweat chloride concentration in a large cystic fibrosis (CF) population.
RESULTS: There was no difference in sweat chloride value value between classes of CFTR mutations that produce no protein (class I), fail to reach the apical membrane because of defective processing (class II), or produce protein that fails to respond to cyclic adenosine monophosphate (class III). Those mutations that produce a cyclic adenosine monophosphate-responsive channel with reduced conductance (class IV) were associated with a significantly lower, intermediate sweat chloride value. However, patients with the mutations that cause reduced synthesis or partially defective processing of normal CFTR (class V) had sweat chloride concentrations similar to those in classes I to III.
CONCLUSION: Studies of differences in chloride conductance between functional classes of CFTR mutations provide insight into phenotypic expression of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472820     DOI: 10.1016/s0022-3476(95)70157-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  54 in total

Review 1.  The pathogenic consequences of a single mutated CFTR gene.

Authors:  U Griesenbach; D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  How to identify the genetic basis of gastrointestinal and liver diseases?

Authors:  P Ferenci
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 3.  Patterns of GI disease in adulthood associated with mutations in the CFTR gene.

Authors:  Michael Wilschanski; Peter R Durie
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

4.  The limitations of sweat electrolyte reference intervals for the diagnosis of cystic fibrosis: a systematic review.

Authors:  Avantika Mishra; Ronda Greaves; John Massie
Journal:  Clin Biochem Rev       Date:  2007-05

5.  Chronic pancreatitis and mutations of the cystic fibrosis gene.

Authors:  C J Taylor
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

6.  Improving care for central nervous system tumours: a mood for change.

Authors:  L S Lashford; D A Walker
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

Review 7.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

Review 8.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

Review 9.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

10.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.